Table 6 Microbiological success rates in microbiologically evaluable patients
| Â | Infusion group, n (%) | Bolus group, n (%) | P- value |
|---|---|---|---|
Eradication overall | 87/96 (90.6%) | 80/102 (78.4%) | 0.020 |
   Verified eradication | 67/96 (69.8%) | 62/102 (60.8%) | 0.233 |
   Presumed eradication | 20/96 (20.8%) | 18/102 (17.6%) | 0.592 |
Culture-based therapy | 82/90 (91.1%) | 74/95 (77.9%) | 0.015 |
Empiric therapy | 5/6 (83.0%) | 5/7 (71.4%) | 1.000 |
Without concomitant ATB therapy potentially active against GNB | 77/85 (90.6%) | 75 (78.1%) | 0.026 |
APACHE II > 20 | 41/47 (87.2%) | 36/49 (73.5%) | 0.125 |
MIC ≥ 1.5 mg/l | 11/14 (78.6%) | 13/21 (61.9%) | 0.292 |
   Acinetobacter spp. | 7/8 (87.5%) | 9/12 (75%) | 0.619 |
   Citrobacter spp. | 3/3 (100%) | 3/4 (75%) | 1.000 |
   Enterobacter spp. | 3/3 (100%) | 7/7 (100%) | n/a |
   Escherichia coli | 5/6 (83.3%) | 7/9 (77.7%) | 1.000 |
   Klebsiella spp. | 58/63 (92.1%) | 39/50 (78.0%) | 0.055 |
   Morganella morganii | 3/3 (100%) | 5/5 (100%) | n/a |
   Pseudomonas aeruginosa | 3/4 (75%) | 3/6 (50%) | 0.571 |
   Serratia marcescens | 4/4 (100%) | 6/6 (100%) | n/a |
   Stenotrophomonas maltophilia | 1/2 (50%) | 1/3 (33.3%) | 1.000 |
Persistence overall | 9/96 (9.4%) | 22/102 (21.6%) | 0.020 |
   Acinetobacter spp. | 0/8 (0%) | 2/12 (16.7%) | 0,495 |
   Citrobacter spp. | 0/3 (0%) | 1/4 (25.0%) | 1.000 |
   Escherichia coli | 1/6 (16.7%) | 2/9 (22.2%) | 1.000 |
   Klebsiella spp. | 5/63 (7.9%) | 11/50 (22.0%) | 0.055 |
   Pseudomonas aeruginosa | 0/4 (0%) | 2/6 (33.3%) | 0.491 |
   Stenotrophomonas maltophilia | 1/2 (50.0%) | 0/3 (0%) | 0.400 |
Resistance | 2/96 (2.1%) | 4/102 (3.9%) | 0.684 |
   Acinetobacter spp. | 1/8 (12.5%) | 1/12 (8.3%) | 1.000 |
   Pseudomonas aeruginosa | 1/4 (25.0%) | 1/6 (16.7%) | 1.000 |
   Stenotrophomonas maltophilia | 0/2 (0%) | 2/6 (33.3%) | 1.000 |